Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data
Completed
- Conditions
- Diffuse Large B-cell LymphomaAcute Lymphoblastic Leukemia (ALL)
- Registration Number
- NCT06392763
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
This retrospective cohort study, based on the French medico-administrative database (SNDS), evaluated the care pathway, the effectiveness of management and the costs associated with patients treated with chimeric antigen receptor (CAR) T cells (CART-cells) (KYMRIAH or YESCARTA): paediatric and young adult patients (up to and including 25 years of age) with acute lymphoblastic leukaemia (ALL); and adult patients (18 years of age or older) with DLBCL.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 602
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of consultations per type of healthcare professional Up to 36 months Number of medicine, surgery, obstetrics and odontology (MCO) stays per patient Up to 36 months Number of outpatient visit (ACE) stays per patient Up to 36 months Number of homecare (HAD) stays per patient Up to 36 months Number of patients who died Up to 36 months Cost of CAR-T on the supplementary list Up to 36 months Cost of medicines on the supplementary list (excluding CAR-T) Up to 36 months Hospitalisation cost Up to 36 months Number of emergency room visits not followed by hospitalisation per patient Up to 36 months Number of aftercare and rehabilitation (SSR) stays per patient Up to 36 months Cost of MCO hospitalisation Up to 36 months Number of consultations per patient (all consultations combined) Up to 36 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Novartis
🇫🇷Rueil-Malmaison, France